RxDoctor Payments Data

Susan Hicks

Family · Knoxville, TNNPI 1477938660

Payments from drug & device makers

$1,200in general payments, 2019–2025

Across 66 payments — averaging $18.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$258
  • Lilly USA, LLC$178
  • AbbVie$118
  • Amgen$102
  • Astellas Pharma US Inc$102
  • Medtronic$100
  • plus $341 from 10 others

What the payments were for

  • Food & beverage$1,200100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk15$258
Lilly USA, LLC11$178
AbbVie7$118
Amgen6$102
Astellas Pharma US Inc4$102
Medtronic5$100
AstraZeneca4$69
Corium, LLC2$62
Merck2$40
Pfizer2$33
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$32
Takeda Pharmaceuticals U.S.A., Inc.2$31
Lundbeck LLC1$24
G Medical Diagnostic Services, Inc.1$23
Vivaquant Inc, Dba Rhythm Express1$14
Grifols USA, LLC1$13

How this compares

$1,200 in reported general payments places this provider in the 65th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$6,836
Medicare patients
16
Services billed
128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide14$24,879
EliquisApixaban18$22,464
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$17,504
OxycontinOxycodone Hcl12$6,370
Tizanidine Hcl19$1,577
Albuterol Sulfate HfaAlbuterol Sulfate29$1,270
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen31$1,060
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen22$811
Hydroxyzine Hcl14$696
Potassium Chloride28$633
Omeprazole28$625
Gabapentin25$622
Oxycodone Hcl35$577
Duloxetine Hcl23$537
Losartan Potassium31$493

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$258$24,87914 claims
PfizerEliquis$33$22,46418 claims
AstraZenecaBreztri Aerosphere$69$17,50416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 6,706 family providers in Tennessee.

Other family in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →